ALX Oncology appoints Alan Sandler as CMO; CFO Garcia departs with separation agreement

ALX ONCOLOGY HOLDINGS INC

Alan Sandler, M.D., appointed Chief Medical Officer effective Nov 10, 2024; base salary $575k, signing bonus $50k, 700k stock options.
Former CFO Peter Garcia resigned Nov 8, 2024; receives $479,646 lump sum, COBRA for 12 months, accelerated equity vesting, and consulting role.
Board reduced to 4 directors; committees set: Audit (Hemrajani chair), Compensation (Goodman chair), Governance (Garland chair).
Dr. Sandler brings 30+ years experience from Mirati, Genentech, Zai Lab; will lead evorpacept development into late-stage trials.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alan Sandler

member of the Board

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-11-10
Filed: November 14, 2024, 6:59 PM ET

Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.

Departed

Peter Garcia

Chief Financial Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-11-08
Filed: November 14, 2024, 6:59 PM ET

As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.

Appointed

Alan Sandler

Chief Medical Officer

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-11-10
Filed: November 14, 2024, 6:59 PM ET

On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Alan Sandler resigned as member of the Board at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: member of the Board

Exact text from the filing

Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Alan Sandler was appointed as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-126749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.